OncoGynecology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "PIK3CA mutation"

PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational status with pCR in patients with HER2-positive early breast cancer treated with ne ...

The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin ) plus chemotherapy increases the pathologic complete remission ( pCR ) rate comp ...

Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free ...